Skip to content
DraconiticResearch
Search Sources API
223,421 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Epidemiology and Infection

Establishing influenza epidemic thresholds and intensity levels in Türkiye using the moving epidemic method and assessing concordance with WHO transmission zones: A sentinel surveillance analysis of ten seasons, 2013–2025

  1. 1Department of Public Health, Division of Epidemiology, Ankara University School of Medicine, Ankara, Türkiye
  2. 2Department of Health Informatics, Graduate School of Informatics, Middle East Technical University, Ankara, Türkiye

Abstract

The Moving Epidemic Method (MEM) is the ECDC/WHO-Europe-endorsed approach for establishing influenza epidemic thresholds and intensity levels, yet no positivity-based MEM analysis exists for Türkiye or any country in the WHO Western Asia transmission zone. Weekly influenza positivity rates from FluNet sentinel surveillance were analysed for ten of twelve seasons (2013/2014–2024/2025, excluding two COVID-19 pandemic seasons) using the mem R package with cross-validated optimized slope parameter, and Türkiye’s average epidemic curve and thresholds were compared with the Western Asia (excluding Türkiye) and South West Europe zones using Lin’s concordance correlation coefficient (CCC), root mean square deviation (RMSD) and complementary correlation metrics. The epidemic threshold was 10.59% positivity, with intensity thresholds at 42.56% (medium), 60.92% (high), and 71.38% (very high); cross-validated sensitivity was 0.77, specificity 0.88, and Matthews correlation coefficient 0.65. Türkiye’s average curve showed higher concordance with Western Asia (CCC=0.890; RMSD=4.22 percentage points) than South West Europe (CCC=0.672; RMSD=12.48) despite similar Pearson correlations (0.922 vs. 0.939), and the Western Asia epidemic threshold (11.50%) closely matched Türkiye’s. These first operational MEM thresholds for Türkiye and the first positivity-based thresholds for the Western Asia zone confirm alignment with the current WHO transmission zone classification and support integration into routine surveillance.

Related

  1. Establishing a human co-infection challenge study of Streptococcus pneumoniae (Spn) and live attenuated influenza vaccine (LAIV) in older healthy adults: E xploring C o-infection with L ive Attenuated I nfluenza Vaccine and P neumococcu S in healthy old E r adults (ECLIPSE), a UK-based single-centre, single-blind randomised controlled trial
    Rebecca I Jackson, Oisin Hennigan, Karen Kelleher +20
    BMJ OpenPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossref
  2. Revisiting alpha-fetoprotein thresholds for hepatocellular carcinoma surveillance in the metabolic dysfunction-associated steatotic liver disease era: time for an evidence-based recalibration.
    Miguel Suárez, Raquel Gómez-Molina, Ana M Torres +1
    Journal of gastrointestinal oncologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMCPMC
  3. Gripenet 2025/26: re-establishing participatory surveillance in Portugal
    V Gómez, AL Saraiva, AP Rodrigues
    The European Journal of Public HealthPeer-reviewedCC BY-NC 4.0Full textEpidemiology & public healthPMCEurope PMC
  4. Adaptive forecasting and alert evaluation for pediatric RSV and influenza hospitalization burden using public U.S. surveillance data: a time-series study
    Jingrong Zhang, Yuying Zhang, Yuhong Lin +3
    BMC Public HealthPeer-reviewedCC BY 4.0Epidemiology & public healthCrossref
  5. 2018–2025 Serological study on avian influenza among occupationally exposed populations in the Poyang Lake area — the region with the highest environmental surveillance positive rate in China
    Chuang Nie, Yawei Li, Wenjing Xie +9
    BMC Public HealthPeer-reviewedCC BY-NC-ND 4.0Epidemiology & public healthCrossref
BibTeX
@article{ontas2026establishing,
  title = {{Establishing influenza epidemic thresholds and intensity levels in Türkiye using the moving epidemic method and assessing concordance with WHO transmission zones: A sentinel surveillance analysis of ten seasons, 2013–2025}},
  author = {Eray Ontas},
  journal = {Epidemiology and Infection},
  year = {2026},
  month = oct,
  doi = {10.1017/s095026882610209x},
  url = {https://doi.org/10.1017/s095026882610209x},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Establishing influenza epidemic thresholds and intensity levels in Türkiye using the moving epidemic method and assessing concordance with WHO transmission zones: A sentinel surveillance analysis of ten seasons, 2013–2025
AU  - Eray Ontas
PY  - 2026
DA  - 2026/10/15
JO  - Epidemiology and Infection
DO  - 10.1017/s095026882610209x
UR  - https://doi.org/10.1017/s095026882610209x
AB  - The Moving Epidemic Method (MEM) is the ECDC/WHO-Europe-endorsed approach for establishing influenza epidemic thresholds and intensity levels, yet no positivity-based MEM analysis exists for Türkiye or any country in the WHO Western Asia transmission zone. Weekly influenza positivity rates from FluNet sentinel surveillance were analysed for ten of twelve seasons (2013/2014–2024/2025, excluding two COVID-19 pandemic seasons) using the mem R package with cross-validated optimized slope parameter, and Türkiye’s average epidemic curve and thresholds were compared with the Western Asia (excluding Türkiye) and South West Europe zones using Lin’s concordance correlation coefficient (CCC), root mean square deviation (RMSD) and complementary correlation metrics. The epidemic threshold was 10.59% positivity, with intensity thresholds at 42.56% (medium), 60.92% (high), and 71.38% (very high); cross-validated sensitivity was 0.77, specificity 0.88, and Matthews correlation coefficient 0.65. Türkiye’s average curve showed higher concordance with Western Asia (CCC=0.890; RMSD=4.22 percentage points) than South West Europe (CCC=0.672; RMSD=12.48) despite similar Pearson correlations (0.922 vs. 0.939), and the Western Asia epidemic threshold (11.50%) closely matched Türkiye’s. These first operational MEM thresholds for Türkiye and the first positivity-based thresholds for the Western Asia zone confirm alignment with the current WHO transmission zone classification and support integration into routine surveillance.
SN  - 0950-2688
SN  - 1469-4409
ER  -